Trevi Therapeutics (NASDAQ:TRVI) Given New $12.50 Price Target at HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI) had its price target raised by HC Wainwright from $7.50 to $12.50 in a report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

TRVI has been the topic of a number of other research reports. D. Boral Capital reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Friday. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a research report on Monday. Finally, Needham & Company LLC lifted their price objective on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $14.56.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $6.07 on Monday. Trevi Therapeutics has a 1-year low of $2.30 and a 1-year high of $7.39. The company has a 50-day moving average of $4.18 and a 200 day moving average of $3.54. The firm has a market capitalization of $466.58 million, a price-to-earnings ratio of -13.80 and a beta of 0.90.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after purchasing an additional 3,283,684 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth approximately $17,099,000. Vivo Capital LLC increased its stake in shares of Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock worth $14,370,000 after buying an additional 1,875,000 shares during the period. Woodline Partners LP increased its stake in shares of Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after buying an additional 2,606,370 shares during the period. Finally, MPM Bioimpact LLC increased its stake in shares of Trevi Therapeutics by 101.2% during the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock worth $12,751,000 after buying an additional 1,556,379 shares during the period. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.